The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI)
decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Background: Heart failure is a common and severe condition, often complicated by diastolic
dysfunction. Current standard therapies such as ACEIs and ARBs have limited efficacy in …

Aims This study aimed to compare the efficacy of angiotensin receptor–neprilysin inhibitor
(ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes …

Objective To investigate whether hypotensive patients diagnosed with heart failure and
reduced ejection fraction (HFrEF) might benefit from angiotensin receptor–neprilysin …

Background Compared to angiotensin inhibition, angiotensin-neprilysin “blockade”
improves mortality and reduces hospitalizations in patients with heart failure (HF) with …

Purpose Sacubitril/valsartan has been demonstrated to improve prognosis and outcomes in
heart failure with reduced ejection fraction (HFrEF) patients. We sought to compare the …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …